Chemokines as the critical factors during bladder cancer progression: an overview.

IF 4.3 4区医学 Q2 IMMUNOLOGY

International Reviews of Immunology Pub Date : 2021-01-01 Epub Date: 2021-02-16 DOI:10.1080/08830185.2021.1877287

Amir Sadra Zangouei, Amir Abbas Hamidi, Hamid Reza Rahimi, Ehsan Saburi, Majid Mojarrad, Meysam Moghbeli

{"title":"Chemokines as the critical factors during bladder cancer progression: an overview.","authors":"Amir Sadra Zangouei, Amir Abbas Hamidi, Hamid Reza Rahimi, Ehsan Saburi, Majid Mojarrad, Meysam Moghbeli","doi":"10.1080/08830185.2021.1877287","DOIUrl":null,"url":null,"abstract":"<p><p>Bladder cancer (BCa) is one of the most frequent urogenital malignancies which is mainly observed among men. There are various genetic and environmental risk factors associated with BCa progression. Transurethral endoscopic resection and open ablative surgery are the main treatment options for muscle invasive BCa. BCG therapy is also employed following the endoscopic resection to prevent tumor relapse. The tumor microenvironment is the main interaction site of tumor cells and immune system in which the immune cells are recruited via chemokines and chemokine receptors. In present review we summarized the main chemokines and chemokine receptors which have been associated with histopathological features of BCa patients in the world. This review highlights the chemokines and chemokine receptors as critical markers in early detection and therapeutic purposes among BCa patients and clarifies their molecular functions during BCa progression and metastasis.</p>","PeriodicalId":14333,"journal":{"name":"International Reviews of Immunology","volume":"40 5","pages":"344-358"},"PeriodicalIF":4.3000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08830185.2021.1877287","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Reviews of Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08830185.2021.1877287","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Bladder cancer (BCa) is one of the most frequent urogenital malignancies which is mainly observed among men. There are various genetic and environmental risk factors associated with BCa progression. Transurethral endoscopic resection and open ablative surgery are the main treatment options for muscle invasive BCa. BCG therapy is also employed following the endoscopic resection to prevent tumor relapse. The tumor microenvironment is the main interaction site of tumor cells and immune system in which the immune cells are recruited via chemokines and chemokine receptors. In present review we summarized the main chemokines and chemokine receptors which have been associated with histopathological features of BCa patients in the world. This review highlights the chemokines and chemokine receptors as critical markers in early detection and therapeutic purposes among BCa patients and clarifies their molecular functions during BCa progression and metastasis.

查看原文本刊更多论文

趋化因子作为膀胱癌进展的关键因素:综述。

膀胱癌(BCa)是最常见的泌尿生殖系统恶性肿瘤之一，主要见于男性。有各种遗传和环境风险因素与BCa进展相关。经尿道内窥镜切除和开放消融手术是肌源性BCa的主要治疗选择。内镜切除后也采用卡介苗治疗，以防止肿瘤复发。肿瘤微环境是肿瘤细胞与免疫系统相互作用的主要场所，免疫细胞通过趋化因子和趋化因子受体募集。现就国内外与BCa患者组织病理特征相关的主要趋化因子及趋化因子受体进行综述。本文综述了趋化因子和趋化因子受体在BCa患者早期发现和治疗中的重要作用，并阐明了它们在BCa进展和转移中的分子功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Reviews of Immunology 医学-免疫学

CiteScore

11.00

自引率

4.00%

发文量

期刊介绍： This review journal provides the most current information on basic and translational research in immunology and related fields. In addition to invited reviews, the journal accepts for publication articles and editorials on relevant topics proposed by contributors. Each issue of International Reviews of Immunology contains both solicited and unsolicited review articles, editorials, and ''In-this-Issue'' highlights. The journal also hosts reviews that position the authors'' original work relative to advances in a given field, bridging the gap between annual reviews and the original research articles. This review series is relevant to all immunologists, molecular biologists, microbiologists, translational scientists, industry researchers, and physicians who work in basic and clinical immunology, inflammatory and allergic diseases, vaccines, and additional topics relevant to medical research and drug development that connect immunology to disciplines such as oncology, cardiovascular disease, and metabolic disorders. Covered in International Reviews of Immunology: Basic and developmental immunology (innate and adaptive immunity; inflammation; and tumor and microbial immunology); Clinical research (mechanisms of disease in man pertaining to infectious diseases, autoimmunity, allergy, oncology / immunology); and Translational research (relevant to biomarkers, diagnostics, vaccines, and drug development).